YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and ...

He Jiankui spent three years in prison after creating gene-edited babies. Now back at work, he sees a greater opening for ...

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

Understand the role of reproductive biotech in overcoming biological limits in fertility treatments and enhancing success ...

Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant expansion of its gene therapy platform.

Gene therapy ‘switch’ may offer non-addictive pain relief. New approach targets pain signals while leaving the rest of the brain untouched.

On the third Tuesday of every month, the Sisters Science Club packs The Belfry, an old church in Sisters turned performance venue, with curious minds eager to learn about the next “Frontier in Science ...

Sulfolobus islandicus, an archaeal model organism, offers unique advantages for metabolic engineering and synthetic biology ...

24/7 Market News (247) is a leading market news platform for public companies. As a pioneer in digital media, 247 is dedicated to the swift distribution of financial market news and information. 247 ...

An updated edition of the Nov. 18, 2025, article. Genomics is a broad and detailed study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this ...